Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Automated Problem and Allergy Lists Enrichment Based on High Accuracy Information Extraction from the Electronic Health Record

    SBC: Clinacuity, Inc            Topic: NCI

    DESCRIPTION provided by applicant Medical errors are recognized as the cause of numerous deaths and even if some are difficult to avoid many are preventable Computerized physician order entry systems with decision support have been proposed to reduce this risk of medication errors but these systems rely on structured and coded information in the electronic health record EHR Unfortunately ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Empowering real time web based genomic big data analysis at commercial scale

    SBC: Frameshift Labs, Inc.            Topic: 172

    DESCRIPTION provided by applicant The academic iobio project delivers web based applications that visualize and provide real time interactive analysis with multiple different data types generated as part of next generation sequencing projects These applications are open source and provided for free This proposal aims to develop critical computational infrastructure to enable the iobio project ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma

    SBC: TheraTarget, Inc.            Topic: 102

    SUMMARY This STTR Phase II proposal addresses the significant need for improved treatment options for patients with liver cancerthe fifth highest incidence of cancer in the worldBecause of the lack of symptomshepatocellular carcinomaHCCis detected at advanced stages inof casesfor which theyear survival rate isand atyears it isThe only curative option for advanced HCC is surgical liver resection an ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government